GDF-8 (Myostatin Inhibitor)

GDF-8, also known as Myostatin, is a negative regulator of muscle growth. Inhibiting GDF-8 through peptide analogs or propeptides has shown promise in increasing muscle mass and preventing muscle wasting in conditions like muscular dystrophy and cachexia. Though animal studies are promising, translation to human therapies has been limited by safety and delivery challenges.

• Inhibits GDF-8 (myostatin) signaling pathway
• Blocks negative regulation of muscle growth
• Prevents activation of Smad2/3 signaling involved in muscle catabolism

• unit: mcg

  low dose: 50

  frequency: 1-2x weekly

  high dose: 200

  standard dose: 100

  administration route: Subcutaneous (SQ)

• Administer 1–2x weekly for up to 12 weeks. Cycle off for 4–8 weeks to evaluate physiological response and minimize hormonal desensitization.

common: ["Injection site irritation or discomfort"]

warnings: ["Possible systemic endocrine effects including suppression of reproductive hormones"]

long term: ["Unknown long-term effects on myostatin-regulated homeostasis and cardiac muscle"]

sequence: Human GDF-8 (Myostatin) Propeptide

half life: Exact duration unknown; varies by formulation

degradation: Metabolized by proteolytic enzymes and tissue peptidases

molecular weight: 25000

molecular formula: C101H170N48O31S8

tissue specificity: Predominantly acts on skeletal muscle satellite cells

• Myostatin: A Skeletal Muscle Chalone.reviewPMID 36266260 ↗
• Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.reviewPMID 34520530 ↗